Our tests have been designed specifically to address the crucial decision-making points in the patient’s treatment journey. The information provided is used actively at these critical points in time to guide a healthcare professional’s decision as to which approved first- through third- and further-line drugs or drug combinations would best suit the individual patient. Our three IndiTreat® CRC tests are CE-marked and available immediately. Decisive innovation in mCRC treatment decision-making IndiTreat® CRC is an innovative in-vitro diagnostic tool that informs decisionmaking for those antineoplastic drugs and drug combinations in mCRC for which no biomarkers exist. IndiTreat® CRC Extend IndiTreat® CRC Start IndiTreat® CRC Explore mCRC patients Treatment sequence Extend Explore Start 3rd - furtherline 1st 2nd -line
RkJQdWJsaXNoZXIy ODY1MjQ=